As part of the first Call for Investment and Technology Acquisition in the Pharmaceutical and Medical Equipment Sector, six innovative projects were presented to the Golrang Pharmaceutical Investment Group in a bid to attract investment.
According to the public relations department of Golrang Pharmaceutical Group, this investment pitch event took place on Tuesday, March 4, 2025, at the Golrang Industrial Group headquarters, attended by the CEO and managers of Golrang Ventures Fund (Golrang’s Venture Capital Fund), along with executives and subsidiary company managers of Golrang Pharmaceutical Group.
The first investment call, launched in October 2024, was a collaborative initiative by Golrang Pharmaceutical Group, Golrang Ventures, and Sharif University of Technology. A total of 87 proposals from 18 provinces across the country were submitted.
Most proposals focused on innovative formulations for chemical and biological drugs, nanomedicines and advanced drug delivery systems, active pharmaceutical ingredients (APIs), digital health systems, smart diagnostic tools, and advanced wound care products.
After an initial screening, 18 projects were shortlisted. Following thorough expert evaluations by the Golrang Pharmaceutical Group’s Drug and Health Innovation Center and Golrang Ventures, six projects made it to the final round.
The Six Finalist Projects:
- Bani Zist-Baspar Hilda (Shiraz) – AriClot hemostatic products
- Fahan Novin Zist-Pouyan (Tehran) – Polymer-based hyaluronic acid microneedles for hydration and anti-wrinkle skincare
- Fazl Daru Pharmaceutical (Mashhad) – Topical ointment containing standardized sinecatechins from natural extracts
- Ruyan Ati-Tech Pharmed (Tehran) – Bioengineered allogeneic wound dressing on silicone
- Raya BioHeal (Tehran) – Self-sampling and HPV detection system for cervical and bladder cancer screening
- Pazhohesh Gostaran Ghazal Pars (Shiraz) – Advanced hemostatic blood clotting pad
Following a final evaluation by expert judges, top-performing teams will receive investment and support from Golrang Pharmaceutical Investment Group and Golrang Ventures Fund.
